Business Wire

Optiscan Signs Know-How Agreement with Mayo Clinic

Share

Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery.

The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic hardware and software development with Mayo Clinic’s know-how in robotic surgery and quality patient care. The agreement, which covers a 24-month co-development plan, will bring together experts from both companies to develop a robot-compatible endomicroscopic imaging system with an initial focus on robotic-assisted breast cancer surgery.

Optiscan CEO and Managing Director, Dr Camile Farah, said: “We’re excited to collaborate with Mayo Clinic to accelerate the development and clinical testing of our robotic imaging platform with the aim of fast-tracking the adoption of real-time digital pathology and image-guided precision robotic surgery. This collaboration is built on a shared history of innovation and a laser focus on delivering the highest quality patient outcomes for better health care delivery.”

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, focussed on transforming health care and building a healthier world. Its drive to deliver better medical care has earned it more top rankings for high-quality patient care than any other health care organization. It has more #1 rankings than any other hospital in the US, and is top-ranked in more specialties than any other US hospital. The hospital undertakes more than 141,000 surgical cases and performs more than 4,000 robotic surgery cases a year.

The robotic-assisted surgery market is experiencing significant growth and is expected to continue expanding driven by technological advancements, increasing adoption, rising prevalence of chronic diseases, an aging population, surgeon demand, and favourable reimbursement policies. The US robotic surgery service market was valued at $1.8 Bn in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 17.3% to reach $6.4 Bn in 2030.

Dr Farah adds: “The collaboration is part of Optiscan’s wider strategic focus on the US market, and its plan to embed its platform technology as a key component of intraoperative oncological surgery workflows in a variety of settings and clinical applications to provide surgeons with real-time microscopic information of cancer clearance for the potential to reduce missed cancers and minimise repeat surgeries due to residual disease.”

Mayo Clinic has a financial interest in the technology referenced in this announcement. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

This announcement has been authorised for release by the Board of Optiscan.

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

To learn more about Mayo Clinic, visit www.mayoclinic.org

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate”, “believe”, “could”, “estimate”, “expect”, “future”, “intend”, “may”, “opportunity”, “plan”, “potential”, “project”, “seek”, “will” and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
M: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Russell Katz
M: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tecnotree Recognized in Two 2025 Gartner ® Hype Cycle™ Reports7.7.2025 17:46:00 EEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, has been recognized in two 2025 Gartner® Hype Cycle™ reports. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707226738/en/ Tecnotree Recognized in Two 2025 Gartner® Hype Cycle™ Tecnotree has been recognized in the following 2025 Gartner Hype Cycle reports: Hype Cycle for Enterprise Communication Services, 2025 for CSP Digital MarketplacesHype Cycle for Operations and Automation in the Communications Industry, 2025 for Partner Ecosystem Management Platforms for CSPs and AI for CSP Customer Interactions We believe that this recognition highlights Tecnotree’s commitment to accelerating CSPs’ digital transformation journeys by offering composable, AI-driven solutions that enable ecosystem monetization, automated customer interactions, and next-gen partner management. These capabilities are part of the Tecnotree Moments and Tecn

Zycus Named a LEADER in 2025 IDC MarketScape for Source-to-Pay7.7.2025 16:41:00 EEST | Press release

Zycus, a global leader in AI-powered procurement technology, has been named a Leader in the IDC MarketScape: Worldwide AI-Enabled Source-to-Pay 2025 Vendor Assessment. This recognition follows a comprehensive evaluation, including RFI submissions, live product demos, analyst briefings, and customer interviews. “Zycus is a recognized Leader in the Source-to-Pay space leveraging Agentic AI to drive procurement transformation. With AI agents like Merlin Intake and the Autonomous Negotiation Agent (ANA), Zycus offers a seamlessly integrated solution suite for enterprises focused on cost savings, risk mitigation, and scalability,” — Patrick Reymann, Research Director, IDC “We believe this recognition underscores our commitment to empowering procurement teams through Merlin Agentic Platform, deep domain expertise, and customer-first innovation,” said Aatish Dedhia, Founder & CEO, Zycus. “With a global product footprint spanning every aspect of the S2P lifecycle, Zycus is proud to support ent

Kevin Egan Joins ClickHouse as Chief Revenue Officer to Accelerate Growth7.7.2025 16:00:00 EEST | Press release

ClickHouse, a leader in real-time analytics, data warehousing, observability, and AI/ML, today announced the appointment of Kevin Egan as Chief Revenue Officer (CRO). With over two decades of experience building and leading enterprise sales organizations at Atlassian, Slack, Dropbox, and Salesforce, Egan will oversee ClickHouse’s global go-to-market functions as demand continues to grow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707959780/en/ Aaron Katz, ClickHouse CEO with Kevin Egan, ClickHouse CRO “I’m incredibly excited to join ClickHouse at such a pivotal time,” said Egan. “As organizations navigate how to compete and thrive in the AI era, ClickHouse is emerging as the de facto database powering the real-time, scalable analytics that AI-driven applications demand. I look forward to building strong relationships not only with forward-thinking customers, but also with our channel and technology partners—working to

Accellix Appoints Dr. Félix A. Montero-Julian as Vice President of Scientific Affairs7.7.2025 15:00:00 EEST | Press release

Accellix, a global leader in rapid point of need cytometry solutions, is pleased to announce the appointment of Félix A. Montero-Julian, PhD as Vice President of Scientific Affairs. Dr. Montero-Julian brings more than 30 years of international experience in scientific affairs, analytical development, and regulatory science to support Accellix’s strategic vision and innovation roadmap. Dr. Montero-Julian joins Accellix from bioMérieux, where he most recently served as Scientific Senior Director of Pharma Quality Control. His previous roles include Cytometry R&D Director at bioMérieux and Director of the Cellular Analysis Department at Beckman Coulter, underscoring a distinguished track record spanning biopharmaceuticals, industrial microbiology, and clinical diagnostics. “I’m excited to join Accellix during this period of dynamic growth and innovation,” said Dr. Montero-Julian. “I have great confidence in the potential of the Accellix Platform to transform quality control in cell and ge

NTT DATA Appoints Anne-Sophie Lotgering as Europe CEO7.7.2025 14:00:00 EEST | Press release

NTT DATA, a global leader in digital business and technology services, today announced the appointment of Anne-Sophie Lotgering as the new Chief Executive Officer for Europe at NTT DATA, Inc., effective 1 September 2025. Lotgering succeeds Chieri Kimura and will report directly to NTT DATA, Inc. President and Global CEO, Abhijit Dubey. She will also join NTT DATA, Inc.’s Executive Leadership Team. Lotgering brings over two decades of leadership experience in IT services and telecommunications, with a strong track record in B2B2C and B2B sales, digital marketing and transformation. She joins NTT DATA from Proximus NXT IT where she served as CEO, overseeing the IT integration of B2B operations across the Netherlands, Luxembourg, and Belgium. Her recent achievements include the successful unification of multiple subsidiaries into a single, agile organization, strategically aligned with high-growth sectors such as cloud, cybersecurity and data. Her career spans senior roles at The Orange G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye